Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 20 analyst ratings
Buy
Strong Buy 30%
Buy 55%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is expected to continue to outperform in the market, with its current growth drivers and potential future high-performing assets, such as its recently acquired Apogee pipeline, contributing to its strong financials and stable market position. The company's strong exposure to immunology and oncology, along with its diversification into other therapeutic areas through recent acquisitions, further strengthens its profitability and resilience in the long term. With its solid track record of cash generation, dividend payout, and commitment to sustainability, AbbVie presents a compelling investment opportunity in the pharmaceutical sector.

Bears say

AbbVie is facing headwinds in key segments such as immunology, oncology, and aesthetics, with numerous competitive threats and pricing pressures. The recent acquisitions of Cerevel and ImmunoGen may not be enough to offset these challenges, and there is a risk of surprise negative trial results for their pipeline assets. Additionally, macroeconomic conditions and a potential rotation away from defensive stocks could also impact the company's performance.

AbbVie (ABBV) has been analyzed by 20 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 55% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 20 analysts, AbbVie (ABBV) has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $277.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $277.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.